| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/17/2002 | US20020006903 Genetic engineering |
| 01/17/2002 | US20020006899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| 01/17/2002 | US20020006898 Trimethyl lock based tetrapartate prodrugs |
| 01/17/2002 | US20020006640 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 01/17/2002 | US20020006432 Bifidobacterium in the treatment of inflammatory disease |
| 01/17/2002 | US20020006417 Heating the fill mass, cooling the fill mass, and encapsulating the fill mass into the capsule immediately after cooling; nutrients or drugs such as saquinavir |
| 01/17/2002 | US20020006398 Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions |
| 01/17/2002 | US20020006383 Promoter of biosynthesis of skin cells |
| 01/17/2002 | US20020006380 Pyrrole derivatives, their preparation and pharmaceutical compositions containing them |
| 01/17/2002 | DE10032132A1 Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung A dermal therapeutic system containing NSAIDs with selective COX-2 inhibition |
| 01/17/2002 | DE10031742A1 Production of cross-linked hemoglobin useful as artificial oxygen carrier comprises cross-linkage of hemoglobin in presence of a chemically inert effector of the hemoglobin oxygen affinity |
| 01/17/2002 | CA2427066A1 Method for the recovery and application of human defensins as biologically active proteins for the treatment of infections and other diseases |
| 01/17/2002 | CA2415808A1 Transporters and ion channels |
| 01/17/2002 | CA2415778A1 Methods of therapy with thrombin derived peptides |
| 01/17/2002 | CA2415624A1 Compositions and methods for treating cardiovascular disorders |
| 01/17/2002 | CA2415547A1 Process for preparing benzoxazin-4-one polymer conjugates |
| 01/17/2002 | CA2415492A1 Pyrazole derivatives |
| 01/17/2002 | CA2415483A1 Antisense compositions targeted to .beta.1 adrenoceptor-specific mrna and methods of use |
| 01/17/2002 | CA2415468A1 Ester derivatives |
| 01/17/2002 | CA2415100A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/17/2002 | CA2415084A1 Olfactory neuron cultures and method of making and using the same |
| 01/17/2002 | CA2415081A1 Drug delivery system for poorly water soluble drugs |
| 01/17/2002 | CA2414938A1 Combinations of ssri and estrogenic agents |
| 01/17/2002 | CA2414480A1 Fatty acid analogues for the treatment of cancer |
| 01/17/2002 | CA2414455A1 Pharmaceutical composition and method for the treatment of retroviral infections |
| 01/17/2002 | CA2414387A1 Drug metabolizing enzymes |
| 01/17/2002 | CA2414272A1 Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
| 01/17/2002 | CA2414112A1 Treatment of male sexual dysfunction |
| 01/17/2002 | CA2414111A1 Use of substituted indole compounds for increasing nitric oxide synthase activity |
| 01/17/2002 | CA2412764A1 Stimulation of cellular regeneration and differentiation in the inner ear |
| 01/17/2002 | CA2412142A1 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/17/2002 | CA2411160A1 Colchinol derivatives as vascular damaging agents |
| 01/16/2002 | EP1172443A1 Method for screening cysteine protease inhibitor |
| 01/16/2002 | EP1172361A1 Sulfonamide derivatives having oxadiazole rings |
| 01/16/2002 | EP1172359A1 N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR |
| 01/16/2002 | EP1172358A1 N-substituted-n'-substituted urea derivative and medicinal compositions containing the same |
| 01/16/2002 | EP1172111A1 Pharmaceutical composition with adhesion molecule expression regulating activity |
| 01/16/2002 | EP1172110A2 Use of lipoic acid as a bioavailaty enhancer of mineral salts |
| 01/16/2002 | EP1172107A1 Drugs containing sulfopyranosylacylglycerol derivatives |
| 01/16/2002 | EP1171626A1 50 human secreted proteins |
| 01/16/2002 | EP1171616A1 Method for enhancing myoblast migration and invasion in the context of gene therapy |
| 01/16/2002 | EP1171613A1 Dsp-7 dual-specificity map kinase phosphatase |
| 01/16/2002 | EP1171599A1 Adipocyte complement related protein homolog zacrp2 |
| 01/16/2002 | EP1171594A1 Vascular endothelial cell growth factor variants and uses thereof |
| 01/16/2002 | EP1171591A1 48 human secreted proteins |
| 01/16/2002 | EP1171590A1 50 human secreted proteins |
| 01/16/2002 | EP1171589A1 A novel family of beta sub-unit proteins from a voltage-gated sodium channel, nucleic acids encoding them and therapeutic or diagnostic uses thereof |
| 01/16/2002 | EP1171585A1 49 human secreted proteins |
| 01/16/2002 | EP1171463A2 Peptide homodimers and peptide heterodimers, derived from interferon alpha 2 |
| 01/16/2002 | EP1171462A2 49 human secreted proteins |
| 01/16/2002 | EP1171460A1 48 human secreted proteins |
| 01/16/2002 | EP1171457A1 46 human secreted proteins |
| 01/16/2002 | EP1171444A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines |
| 01/16/2002 | EP1171442A1 Xanthine derivatives and analogs as cell signalling inhibitors |
| 01/16/2002 | EP1171441A1 Morphinoid compounds |
| 01/16/2002 | EP1171440A1 Substituted-3-cyano-[1.7],[1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases |
| 01/16/2002 | EP1171438A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171431A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171428A1 Fab i inhibitors |
| 01/16/2002 | EP1171425A1 Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins |
| 01/16/2002 | EP1171424A1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 01/16/2002 | EP1171422A1 Mmp inhibitor |
| 01/16/2002 | EP1171419A1 Biphenyl derivatives as antagonists of the neurokinine-1 receptor |
| 01/16/2002 | EP1171414A1 Compounds, their preparation and use |
| 01/16/2002 | EP1171165A1 Intramyocardial injection of autologous bone marrow |
| 01/16/2002 | EP1171161A1 Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid |
| 01/16/2002 | EP1171160A1 Method and means for treating post-polio syndrome |
| 01/16/2002 | EP1171154A2 Uses of mammalian ox2 protein and related reagents |
| 01/16/2002 | EP1171151A1 Thrombospondin-2 and uses thereof |
| 01/16/2002 | EP1171149A1 Inhibition of proteasome function induces programmed cell death in endothelial cells |
| 01/16/2002 | EP1171147A1 Modulation of excitable tissue function by peripherally administered erythropoietin |
| 01/16/2002 | EP1171144A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa |
| 01/16/2002 | EP1171143A1 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising same |
| 01/16/2002 | EP1171142A1 Inflammatory mediation obtained from atractylodes lancea |
| 01/16/2002 | EP1171136A2 Immunomodulating composition for use especially in the treatment of inflammations, infections and surgical adhesions |
| 01/16/2002 | EP1171131A1 Medicaments containing inhibitors of cell-volume regulated human kinase h-sgk |
| 01/16/2002 | EP1171130A1 Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same |
| 01/16/2002 | EP1171129A1 Use of glucosylceramide synthesis inhibitors in therapy |
| 01/16/2002 | EP1171128A1 Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy |
| 01/16/2002 | EP1171127A2 Pharmaceutical compositions containing pyridine or pyrimidine derivatives for inhibition of cytokine production and secretion |
| 01/16/2002 | EP1171125A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/16/2002 | EP1171122A1 Pyrrolidine modulators of chemokine receptor activity |
| 01/16/2002 | EP1171121A2 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth |
| 01/16/2002 | EP1171118A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues |
| 01/16/2002 | EP1171109A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP1171093A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP1170993A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
| 01/16/2002 | EP1121926A9 Cosmetic preparations containing Waltheria indica extracts |
| 01/16/2002 | EP0880517B1 Quinazoline compounds |
| 01/16/2002 | EP0832073B1 Quinazolines and pharmaceutical compositions |
| 01/16/2002 | EP0638075B1 Thiazole or imidazole derivatives as maillard reaction inhibitors |
| 01/16/2002 | CN1331797A High energy phototherapeutic agents |
| 01/16/2002 | CN1331701A Modified peptides as therapeutic agents |
| 01/16/2002 | CN1331694A Antihistaminic spiro compounds |
| 01/16/2002 | CN1331692A Benzisozazoles and phenones as alpha antagonist |
| 01/16/2002 | CN1331691A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331688A Aminopyrazole derivatives |
| 01/16/2002 | CN1331683A 2-phenylbenzimidazoles and 2-phenylindoles, and prodn. and use thereof |